Formosa Pharmaceuticals, Inc.’s Post

Exciting updates from Richard Francis, CEO of Teva Pharmaceuticals, yesterday at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York City (New York) about the pivotal Phase 3 of Olanzapine LAI powered by Medincell technology: > No PDSS observed after completion of c.c.99% of the targeted injections for submission have been performed as of today > confirmation that the full submission safety results are expected to be available in H2 24. > Replay of the conference available here: https://lnkd.in/dBWQssTM > Press release: https://lnkd.in/dWwvNWD5   Olanzapine LAI is an investigational once-monthly subcutaneous long-acting injection of the atypical antipsychotic Olanzapine. It has the potential to be the first long-acting Olanzapine with a favorable safety profile.

Following up on our article on clinical development and deal trends in targeted radiopharmaceuticals (https://lnkd.in/ecDEsU5y), we've published an article summarizing the targeted radiopharmaceutical journey (https://lnkd.in/e5g-ejgR). Our latest article focuses on barriers to these medicines reaching more patients and realizing their full commercial potential, and how to mitigate those barriers. #radiopharmaceuticals #radioconjugate #RLT

X4 Pharmaceuticals, a partner of our portfolio company Abbisko, has received FDA approval for its CXCR4 antagonist Xolremdi (mavorixafor) capsules. This new treatment option is tailored for patients aged 12 and older who are dealing with WHIM syndrome, aiding in the increase of mature neutrophils and lymphocytes in the bloodstream. This marks the first approved treatment specifically for those battling WHIM syndrome. Abbisko and X4 reached an exclusive license agreement permitting the development, production, and commercialization of licensed compound ABSK081 (mavorixafor) products within the fields of diagnosis, treatment, relief, or prevention of any human tumor indications and WHIM syndrome in Chinese mainland, Hong Kong, Macao and Taiwan regions. #QMportfolio #QMhealthcare #healthcare #medicinenews #FDAapproval #WHIMsyndrome #Abbisko #X4Pharmaceuticals

One thing I enjoy about working in Cell, Gene, and Advanced Therapies, such as targeted radiopharmaceuticals (TRPs), is solving complex problems that require a nuanced understanding of the underlying science. I particularly enjoyed working on this whitepaper, which focused on the barriers in TRP development and offered ideas on how companies can overcome these challenges to bring these innovative therapies to more patients. #TargetedRadioPharmaceutical #AdvancedTherapies #radiopharma

BREAKING NEWS: Meitheal Pharmaceuticals Launches Dacarbazine for Injection. Amidst a time of injectable drug shortages, Meitheal is proud to introduce Dacarbazine for Injection, USP 200 mg per vial, NDC – 71288-174-21, now available in a single-dose vial. "We are thrilled to bring Dacarbazine to the United States Market," declared Tom Shea, Chief Executive Officer of Meitheal Pharmaceuticals. "At Meitheal, we recognize the critical importance of a reliable drug supply. The launch of Dacarbazine exemplifies our steadfast commitment to ensuring sustainability of essential medications in the United States. By delivering on our promises, we empower our customers to effectively meet the needs of their patients." Dacarbazine for Injection, USP is indicated in the treatment of metastatic malignant melanoma, addressing a crucial therapeutic need. This launch underscores Meitheal's dedication to advancing patient care and contributing to the broader healthcare landscape. Learn more about Dacarbazine here: https://lnkd.in/dMBMHunx  Think sustainability, think Meitheal. #Sustainability #Meithal #NewProductLaunch #PatientCare #HealthcareInnovation

🌟 Vertex Pharmaceuticals Unveils Full Phase III Data for Non-Opioid Pain Candidate! 🌟 Vertex Pharmaceuticals has shared promising Phase III results for Suzetrigine, its investigational non-opioid pain treatment. The drug demonstrated a cleaner safety profile than standard treatments, like hydrocodone/acetaminophen, while showing significant pain relief in abdominoplasty patients. 🚀 Though some challenges remain, especially in comparison to current options in the acute pain market, this is an important step toward non-opioid solutions! 💊✨ #Pharma #DrugDevelopment #NonOpioid #PainManagement #VertexPharma #ClinicalTrials #HealthcareInnovation

Real-world Pearls for iDose TR Implantation: Information on initial experience complements clinical trial data. By Savak “Sev” Teymoorian, MD, MBA #sustaineddelivery #glaucoma #proceduralpharmaceutical #glaucomasurgery Read this article in our current issue at the link in bio.

Explore Novotech's latest whitepaper, which highlights recent advancements and market insights in radiopharmaceuticals. #DidYouKnow that over the past five years, global clinical trials in the radiopharmaceutical sector have surged by 96%, led by North America at 42%, followed by the Asia-Pacific region at 28% and Europe at 26%? For more information, download our latest whitepaper- https://lnkd.in/d9B7wXuA #Radiopharmaceuticals #ClinicalTrials #Novotech

Sun Pharma and Moebius Medical gain fast track designation for MM-II for the treatment of Osteoarthritis Knee Pain. Sun Pharmaceutical Industries (and its subsidiaries or associate companies) and Israel-based Moebius Medical announced that the US Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to MM-II (Large Liposomes of DPPC and DMPC) for the treatment of osteoarthritis knee pain. Planning for confirmatory Phase 3 clinical trials for MM- II is underway. MM-II is a novel non-opioid product that uses a proprietary suspension of large, empty, multilamellar liposomes which are intended to reduce friction and wear on the joint and thus relieve joint pain.